No previous studies have reported KDD in ERBB2, ERBB3, and ERBB4. These data indicate that ERBB-KDDs account for a small but significant fraction of ERBB family-mediated cancers, and suggest utility of approved targeted therapies for patients based on standard of care clinical genomic testing. The gene discussed is EGFR; the disease is cancer.